Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

肾损伤分子 1 (KIM-1) 作为肾细胞癌生物标志物的临床特征

• 批准号: 10365631
• 负责人: David McDermott
• 金额: $ 45.42万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-15 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10365631
• 关键词: Address; Adjuvant; Adjuvant Study; Adjuvant Therapy; Angiomyolipoma; BAY 54-9085; Biological Markers; Blood; Blood Tests; Blood specimen; Case-Control Studies; Cessation of life; Clear Cell; Clinical; Clinical Trials; Cohort Studies; Collection; Cyst; Data; Diagnosis; Disease; Disease-Free Survival; Eastern Cooperative Oncology Group; Enrollment; European; Excision; Future; Gene Expression Profile; Goals; Histologic; Immunoglobulins; Immunotherapy; Individual; Injury to Kidney; Integral Membrane Protein; International; International Agency for Research on Cancer; Kidney Neoplasms; Lead; Localized Disease; Malignant Neoplasms; Measures; Medical center; Metastatic Renal Cell Cancer; Monitor; Mucins; Nephrectomy; Operative Surgical Procedures; Outcome; Papillary; Pathologic; Pathology; Patients; Phase; Phase III Clinical Trials; Plasma; Prognosis; Prognostic Factor; Prognostic Marker; RNA; Randomized; Recurrence; Renal Cell Carcinoma; Renal Mass; Resected; Retrospective cohort; Risk; Risk Assessment; Sampling; T-Lymphocyte; Testing; Time; Validation; Work; blood-based biomarker; checkpoint therapy; circulating biomarkers; clinical prognostic; cohort; diagnostic biomarker; high risk; immune checkpoint; immunoregulation; improved; mortality; outcome prediction; patient population; predict clinical outcome; prognostic; prospective; rat KIM-1 protein; relapse prediction; relapse risk; risk stratification; targeted treatment; treatment response; tumor

Project Summary While there are many treatment options for patients with metastatic RCC, it is still a deadly disease with considerable mortality. RCC can be much more effectively treated if it is detected early when it is amenable to surgery. To date there is no biomarker for RCC. Additionally, A specific and sensitive circulating biomarker could not only help detect this cancer earlier but could also aid in the diagnosis and monitoring of disease. This proposal seeks to test the utility of circulating kidney injury molecule-1/ T cell immunoglobulin mucin domain-1 (KIM-1/ TIM-1) as a blood test that can be used to follow patients with small renal masses and with the goal of safely avoiding or delaying surgery. We will also measure KIM1 in patients with resected RCC with the goal of identifying a high-risk patient population most likely to benefit from adjuvant therapy after nephrectomy for localized disease. This proposal will also test KIM-1 as a blood test that can help follow response to therapy for metastatic disease. To prepare for submission our team has spent considerable time and effort in identifying readily available patient samples to answer our questions. In this proposal we are poised and have samples available to address all of these questions. We hope that in the future, prospective trials will test KIM-1 in these settings but at this time, rigorous testing in these retrospective cohorts will provide the groundwork for these future studies.

项目摘要 虽然转移性RCC患者有很多治疗选择，但它仍然是一种致命疾病 死亡率很大。如果RCC可以提早检测到RCC，则可以更有效地治疗 外科手术。迄今为止，RCC还没有生物标志物。另外，特定敏感的循环生物标志物 不仅可以帮助更早地检测到该癌症，还可以帮助诊断和监测疾病。 该建议旨在测试循环肾损伤分子1/ T细胞免疫球蛋白粘蛋白的效用 域-1（KIM-1/ tim-1）作为血液检查，可用于跟踪肾脏较小的患者，并且 安全避免或延迟手术的目的。我们还将测量切除的RCC患者的KIM1 确定最有可能受益于辅助治疗后的高风险患者人群的目的 用于局部疾病的肾切除术。该建议还将测试KIM-1作为血液检查，可以帮助 遵循对转移性疾病治疗的反应。为了准备提交我们的团队已经花费了 大量的时间和精力来识别随时可用的患者样本来回答我们的问题。在 这项建议我们已经准备好，并提供了可以解决所有这些问题的样本。我们希望 未来，前瞻性试验将在这些环境中测试KIM-1，但此时，在这些情况下进行了严格的测试 回顾性队列将为这些未来的研究提供基础。